01——PLI scheme for bulk drugs may see 20 projects worth Rs. 840 crore up and running by March 31 根据印度http://PHARMABIZ.COM,当地最全面的医药综合门户网站2月26日的新闻:印度将在3月31日全面开启原料药PLI计划。 在PLI原料药生产挂钩激励计划下,当地政府构想了20个项目,以支持印度制药公司实现原料...
This scheme holds the potential to transform India into a global leader in pharmaceutical production and enhance its self-sufficiency in critical bulk drugs and Active Pharmaceutical Ingredients (APIs). By providing financial incentives based on incremental sales and setting criteria for eligibility,...
The Scheme has been designed with an objective to attain self-reliance and reduce import dependence in these critical bulk drugs as India country is significantly dependent on the import of basic raw materials, viz., bulk drugs that are used to produce medicines. In some specific bulk drugs, t...
The major objective of the PLI scheme is to reduce import dependency and boost the domestic production of bulk drugs. Currently, India imports nearly 68 per cent of API, by value, from China. The import of APIs has risen at a CAGR of 8.3 per cent from 2012 to 2019 and the bulk drug ...
pharmaceutical ingredients (APIs)/intermediates under category 2 of Rs. 15,000 crore production linked incentive (PLI) scheme as long as they are import substitution and there is domestic value addition of 70 per cent for chemical synthesis based bulk drugs and 90 per cent for fermentation based...
As of today, DoP has granted approvals to 16 firms to manufacture drugs under the PLI scheme to incentivise domestic pharmaceutical sector. As per the guidelines of PLI scheme for boosting indigenous production of 41 products which cover all the identified 53 APIs for which India is critically ...
methanol biomass. The mixture was kept under continuous stirring for 20 min to obtain the ZnO nanoparticles precipitate. The obtained precipitate was centrifuged and washed with an excess of methanol several times, followed by deionized water, and then oven dried for 4 h at 80 °C (Scheme 1)...